PT Kalbe Farma Tbk. (KLBF.JK) Stock

KLBF.JK logo

PT Kalbe Farma Tbk.

KLBF.JKIndonesia
Healthcare

Company profile

PT Kalbe Farma Tbk. reported revenue of 32.63 trillion IDR for fiscal year 2024, up 7.2% from fiscal year 2023, and net income of 3.24 trillion IDR. That is a net profit margin of 9.9% for fiscal year 2024. In Q2 2025 (the quarter ended June 30, 2025) revenue was 8.23 trillion IDR, up 3.4% from a year before. Its largest business segment, Distribution and Logistic, brought in 35% of segment revenue in fiscal year 2025; Indonesia was the largest region with 93%. In Q2 2025 it reported net income of 898.17 billion IDR, against net income of 847.54 billion IDR a year earlier. Our analysis of its filings shows revenue growing from 28.93 trillion IDR in fiscal year 2022 to 32.63 trillion IDR in fiscal year 2024, 6.2% a year on average. PT Kalbe Farma Tbk. reports about 12,726 full-time employees.

What stands out

  • Revenue in fiscal year 2024 was the highest of the last 5 fiscal years.

Figures from company filings; latest fiscal year ended December 31, 2024.

About PT Kalbe Farma Tbk.

PT Kalbe Farma Tbk., together with its subsidiaries, engages in the development, manufacture, and trading of pharmaceutical products in Indonesia. It operates through Prescription Pharmaceuticals; Consumer Health; Nutritionals; and Distribution and Logistic segments. The company provides prescription/ethical; consumer health; nutritionals; distribution and logistics; health services; medical devices; biopharma; animal health; international business, and E-health products. In addition, the company provides health screening services; operates as an agent and representative for biotechnology products; distributes consumer products, medical equipment, cosmetics, and other trading products; and trades in medical and laboratory equipment and supplies, raw materials for pharmaceutical products, and consumable products for hemodialysis therapy, as well as offers advertising services. The company was incorporated in 1966 and is headquartered in Jakarta, Indonesia.

Largest shareholders

  • Theresia Harshini10.47 %10.47%
  • Khouw Lip Swan10.31 %10.31%
  • Boenjamin Setiawan10.08 %10.08%
  • Maria Karmila9.484 %9.48%
  • Gerda Veronica9.297 %9.30%

Share of the company, as of September 25, 2026

Leadership

  • Bernadette Ruth Irawati Setiady MSc. — President Director, 63
  • Sie Djohan — Director of Corporate Business Development, Management System & Regulatory Affairs and Director, 58
  • Rustam Tan — Head of Internal Audit Unit, 55
  • Maria Teresa Fabiola — Corporate Secretary, 53

How much revenue does PT Kalbe Farma Tbk. make?

PT Kalbe Farma Tbk. reported 32.63 trillion IDR in revenue for fiscal year 2024, up 7.2% from 30.45 trillion IDR in fiscal year 2023. In Q2 2025 revenue was 8.23 trillion IDR.

What is PT Kalbe Farma Tbk.'s largest business segment?

Distribution and Logistic, with 12.21 trillion IDR or 35% of segment revenue in fiscal year 2025. Next: Prescription Pharmaceutical (29%) and Nutritionals (23%).

Where does PT Kalbe Farma Tbk. make most of its revenue?

Indonesia: 93% of revenue by region in fiscal year 2025, followed by Exports (7%).

What companies are similar to PT Kalbe Farma Tbk.?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include PT Tempo Scan Pacific Tbk (TSPC.JK), PT Darya-Varia Laboratoria Tbk (DVLA.JK), PT Merck Tbk (MERK.JK), PT Pyridam Farma Tbk (PYFA.JK).

How has PT Kalbe Farma Tbk.'s revenue changed over the last 5 fiscal years?

Revenue by fiscal year: FY2020, 23.11 trillion IDR; FY2021, 26.26 trillion IDR; FY2022, 28.93 trillion IDR; FY2023, 30.45 trillion IDR; FY2024, 32.63 trillion IDR.

Company Information

SectorHealthcare
IndustryMulti-Therapeutic Drug Manufacturing
Employees12,726
Founded1966
IPO DateJul 30, 1991
IPO StatusPublic
HeadquartersJakarta, Indonesia
FoundersBoenjamin Setiawan
ExchangeJakarta
TimezoneAsia/Jakarta (WIB)

Contact & Links

Address
Gedung KALBE, Jakarta, 10510
Phone
62 21 4287 3888
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “PT Kalbe Farma Tbk. (KLBF.JK)”, data as of Sep 25, 2026, https://dataporium.tech/stocks/KLBF.JK

LinkedInLinkedInXXYouTubeYouTube